Find stats on top websites
Industry Landscape
The global fertility services market is experiencing significant growth, driven by factors such as rising infertility rates, delayed parenthood, increasing awareness, and technological advancements in Assisted Reproductive Technologies (ART). Personalized medicine and genetic testing are becoming more prevalent. While costs remain a barrier for many, increased insurance coverage and financing options are expanding accessibility. The market is competitive, with clinics focusing on success rates and patient experience.
Total Assets Under Management (AUM)
Number of ART cycles performed in United States
~Approximately 330,000 ART cycles (including IVF) were performed in the United States in 2021. (CDC, 2021 Assisted Reproductive Technology Fertility Clinic Success Rates Report)
(3-5% CAGR)
- Increase in number of people seeking fertility treatments.
- Advancements in technology expanding treatment options.
- Growing awareness and reduced stigma around infertility.
Total Addressable Market
9.2 billion USD
Market Growth Stage
Pace of Market Growth
Emerging Technologies
AI-Powered Diagnostics & Personalization
Artificial Intelligence is being used to analyze vast datasets of patient information to predict IVF success rates, optimize treatment protocols, and personalize medication dosages, leading to higher efficiency and better outcomes.
Advanced Genetic Screening (PGT)
Next-generation sequencing (NGS) and advanced bioinformatics are enhancing Preimplantation Genetic Testing (PGT) to more accurately identify chromosomal abnormalities and single-gene disorders in embryos, improving implantation rates and reducing genetic risks.
CRISPR Gene Editing
CRISPR technology holds future potential for correcting genetic defects in embryos that cause inherited diseases, though its ethical and regulatory implications are still under extensive debate and research.
Impactful Policy Frameworks
California Fertility Mandate (2020 Amendment)
While California has had a fertility mandate since 1989, recent amendments (e.g., AB 775 in 2020) have aimed to clarify and expand coverage requirements for employers, including group health plans, for infertility diagnosis and treatment.
This policy potentially increases accessibility to fertility treatments for a broader patient base, driving higher demand for OC Fertility's services by reducing the financial burden on patients.
FDA Regulations on Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) (ongoing updates)
The FDA continues to update and enforce regulations (21 CFR Part 1271) governing the donation, processing, storage, and distribution of HCT/Ps, which include reproductive tissues like oocytes and sperm used in ART.
These regulations ensure the safety and quality of materials used in ART, requiring OC Fertility to maintain strict adherence to laboratory and handling protocols, thereby potentially increasing operational costs but ensuring patient safety.
State-level PGT and Embryo Disposition Laws (Varying by State)
While not a single federal policy, various states are increasingly enacting or debating laws regarding the legal status of embryos and the scope of preimplantation genetic testing, which can impact clinical practice.
OC Fertility must remain vigilant about evolving state-specific laws on embryo status and PGT, as these could influence patient counseling, consent processes, and available testing options.
Transform Your Ideas into Action in Minutes with WaxWing
Sign up now and unleash the power of AI for your business growth
